Nachrichten zur Eli Lilly & Co. Aktie

Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold @themotleyfool #stocks $NVO $LLY

The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its…

Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold

The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its…

Here are Wednesdays biggest analyst calls: Nvidia, Netflix, Amazon, Apple, Tesla, Verizon, Eli Lilly & more

Here are Wednesdays biggest calls on Wall Street.…

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

…

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimers. Mounjaro and Zepbound are expected to…

Why Eli Lilly Stock Could Start Off 2024 With a Bang

Investors shouldnt assume Eli Lillys stock has peaked.…

Why Eli Lilly Stock Could Start Off 2024 With a Bang @themotleyfool #stocks $LLY

Investors shouldnt assume Eli Lillys stock has peaked.…

Eli Lilly takes early lead in weight loss drug race, BMO says

…

Eli Lilly completes small buy of cancer drugmaker — the payoff may come later

Eli Lillys Point Biopharma acquisition doesnt change our optimism on the diabetes-and-obesity drug giant heading into the new year.…

Obesity and Alzheimers drugs pack one-two punch to power Eli Lilly higher in 2024

After climbing 55% in 2023, Eli Lillys stock still has room to grow.…

Eli Lilly purchase of Point Bio to close Wednesday after tender offer completed

…

Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade)

…

Global Injection Pen Market Analysis and Forecast to 2028, Featuring Analysis of Key Players Sanofi, Eli Lilly, Novo Nordisk, Becton Dickinson, AstraZeneca, F. Hoffmann-La Roche & Merck

Dublin, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Injection Pen Market: Analysis By Type, By Therapy, By…

Eli Lilly: Long Path To A Trillion

…

New weight-loss-drug rivals to Eli Lilly and Novo Nordisk in 2024?

…

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and…

Eli Lilly Looks Overvalued, Buy Pfizer Instead

…

Eli Lilly stock could soar 140% by 2028 as more people use weight-loss drugs, Goldman says

Sandy Huffaker for The Washington Post via Getty Images Eli Lilly stock could soar 140% by 2028 as millions of…

Eli Lilly stock could soar 140% by 2028 as more people use weight-loss drugs, Goldman says

…

5 Big Drug Stocks That May Continue to Outperform in 2024

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year.…

Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook

The launch of Eli Lillys weight-loss drug Zepbound is going swimmingly in the U.S., Jefferies said Friday.…

Where Will Eli Lilly Be in 5 Years?

Theres a lot of growth still to come for this healthcare behemoth.…

Where Will Eli Lilly Be in 5 Years? @themotleyfool #stocks $LLY

Theres a lot of growth still to come for this healthcare behemoth.…

Eli Lilly: Der erste Billionen-Dollar-Pharma-Konzern?

Das amerikanische Pharma-Unternehmen Eli Lilly schwimmt auf der Erfolgswelle. Der Grund dafür ist vor allem der Hype um einen Wirkstoff:…

Breast Cancer Drugs Global Market Report 2024, Featuring Profiles of Key Players Novartis, AstraZeneca, Eli Lilly, Biocon, Merck and MacroGenics

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added…

Renowned investor Ken Langone sees Eli Lilly going to $1 trillion for the same reason we took a stake

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Stakeholder rights law firm Johnson Fistel, LLP has launched an…

Better Weight Loss Stock: Eli Lilly or Novo Nordisk?

Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however.…

Better Weight Loss Stock: Eli Lilly or Novo Nordisk? @themotleyfool #stocks $LLY $NVO

Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however.…

LLY Down as Patients Regain Weight After Stopping Zepbound

Full results from a late-stage study show that patients who stopped taking Eli Lillys (LLY) weight-loss drug for over a…

AKTIE IM FOKUS: Studiendaten belasten Pharma-Schwergewicht Eli Lilly

NEW YORK (dpa-AFX) - Aktuelle Daten zum Abnehmmittel Zepbound (Tirzepatide) haben den in diesem Jahr bislang…

Eli Lilly sell-off shows investors are misinterpreting a study that we view as positive

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

The sell-off of Eli Lilly stock shows investors are misinterpreting a study that we view as a positive

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

Novo-Nordisk-Konkurrent Eli Lilly: Studiendaten zu Abnehmmittel setzen Aktie unter Druck

Die Aktie des Pharmakonzerns Eli Lilly muss am heutigen Montag kräftig Federn lassen. Mehr als drei Prozent geht es bei…

Novo-Nordisk-Konkurrent Eli Lilly: Studiendaten zu Abnehmmittel setzen Aktie unter Druck

Die Aktie des Pharmakonzerns Eli Lilly muss am heutigen Montag kräftig Federn lassen. Mehr als drei Prozent geht es bei…

Patients regain weight after stopping Eli Lillys Zepbound, study says

The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.…

Stocks making the biggest moves midday: Macys, Cigna Group, Eli Lilly, Paramount and more

These are the stocks posting the largest moves in midday trading.…

AKTIE IM FOKUS: Eli Lilly sehr schwach nach gutem Lauf und Studiendaten

NEW YORK (dpa-AFX Broker) - Die Aktien von Eli Lilly sind am Montag nach einem…

Eli Lilly obesity drug patients regained weight after ending treatment: study

Individuals using Eli Lilly and Co (NYSE:LLY)’s obesity drug Zepbound (tirzepatide) regained weight after they stopped using the treatment, according…

Eli Lilly slips as weight loss drugs effect reverses after therapy

…

Eli Lilly slumps after disappointing Zepbound weight-loss-drug trial

Zepbound, which Eli Lilly had hoped would offset the slide in Trulicity sales, had mixed results in a major clinical…

ALLR: Stenoparib Clinical Update

By John Vandermosten, CFA NASDAQ:ALLR Early Results - Phase II Stenoparib Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lillys P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge…

Should You Buy Eli Lilly Stock Now or Wait for a Dip? @themotleyfool #stocks $LLY

Eli Lillys P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge…

Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?

Theres no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has…

Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks

Shares in Eli Lilly are up around 60% year-to-date, while Novo Nordisk has gained around 50%. Should investors buy either…

Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages

Eli Lillys drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.…

POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?

SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stakeholder rights law firm Johnson Fistel, LLP has launched an…

Eli Lillys weight loss drug Zepbound is now available at US pharmacies

Eli Lilly and Co (NYSE:LLY) announced that its weight loss drug Zepbound is now available at pharmacies in the US,…

Eli Lilly’s New Weight-Loss Drug Now on Sale to Rival Hard-to-Find Wegovy

Eli Lilly & Co.’s new weight-loss drug Zepbound is now available at US pharmacies, offering an alternative to rival medications…